research reports and media, page-4230

Denial,


Yeah looks that way, I firmly believe we definitely still need a 003 (or equivalent), the emphasis is now getting 012 passed and approved. Indeed the 012 is the new 002 Part 2.

Im very happy n has reduced, this shows the strength of the stats.

Remember the bio statistician would've approved this and are happy with it to be submitted to the FDA.I know who that primary statistician is, (and you do too, that was mentioned at the last AGM)...Jim B, a legend in the industry. Par would also be using their own stat. group too no doubt. This is very good for us.

The addition and expansion by including that durational endpoint is superb news for us longer term. It will add spades to a deal proposition, metrics and the eventual revenue and uptake. Its not just for the long term benefit though ............Deals come before revenue.

Well, usually.





Spec chatter here, personal thoughts.